The cerebral deposition of amyloid ␤-peptide, a central event in Alzheimer's disease (AD) pathogenesis, begins several years before the onset of clinical symptoms. Noninvasive detection of AD pathology at this initial stage would facilitate intervention and enhance treatment success. In this study, high-field MRI was used to detect changes in regional brain MR relaxation times in three types of mice: 1) transgenic mice (PS/APP) carrying both mutant genes for amyloid precursor protein (APP) and presenilin (PS), which have high levels and clear accumulation of ␤-amyloid in several brain regions, starting from 10 weeks of age; 2) transgenic mice (PS) carrying only a mutant gene for presenilin (PS), which show subtly elevated levels of A␤-peptide without ␤-amyloid deposition; and 3) nontransgenic Cerebral deposits of the amyloid ␤-peptide and alterations of neurophysiology develop some years before Alzheimer's disease can be diagnosed clinically (1-3). By this stage, brain pathology is extensive and includes irreversible loss of neurons in brain regions essential for normal cognition (3). Because AD therapy is likely to be most successful when intervention occurs before neurons are irreversibly damaged or lost, noninvasive methods to detect early yet subtle changes in the brain would have considerable clinical value. Currently, there are no sensitive and specific biological markers for the preclinical stages of AD.
Cerebral deposits of the amyloid ␤-peptide and alterations of neurophysiology develop some years before Alzheimer's disease can be diagnosed clinically (1) (2) (3) . By this stage, brain pathology is extensive and includes irreversible loss of neurons in brain regions essential for normal cognition (3) . Because AD therapy is likely to be most successful when intervention occurs before neurons are irreversibly damaged or lost, noninvasive methods to detect early yet subtle changes in the brain would have considerable clinical value. Currently, there are no sensitive and specific biological markers for the preclinical stages of AD.
Recent MRI studies of humans with mild cognitive impairment have shown that brain volume losses associated with neurodegeneration in the hippocampus have value in predicting increased risk for developing AD (4, 5) . Moreover, advances in high field strength MRI technology now raise the possibility that more subtle alterations of morphology or physiology preceding neurodegeneration might be detectable, including, in the case of AD, early effects of ␤-amyloid deposition. Since intrinsic MR parameters, such as transverse (T 2 ) and longitudinal (T 1 ) relaxation times are sensitive to changes in the biophysical environment of water, we hypothesized that the presence of increased deposition of ␤-amyloid in the brain would have an effect on these parameters.
To investigate the possibility of early detection of the pathophysiology associated with AD, we studied PS/APP and PS transgenic mice together with nontransgenic (NTg) controls with MRI at 7 T. PS transgenic mice carry only a mutant gene for presenilin-1 (PS), which show subtly elevated levels of A␤-peptide without ␤-amyloid deposition in the brain (6) . PS/APP transgenic mice express the human genes for amyloid precursor protein (APP) and presenilin-1 (PS) (7), which harbor mutations, APP K670N,M671L and PS M146V , known to cause familial AD (FAD) in humans. In these mice, ␤-amyloid begins to deposit at 10 -12 weeks of age and progressively accumulates as plaque-like lesions throughout their life span, reaching levels exceeding those in AD brain. Several other features of the human disease are also seen, including dystrophy of some neurites and mild local inflammation within the plaques (8); however, neurofibrillary tangle formation is absent and neuronal cell loss has not been detected by stereological analysis (9) . These mice, therefore, represent a model of extensive ␤-amyloidosis with a level of tissue injury corresponding most closely to the early stages of AD.
In this study, we acquired quantitative parametric maps of transverse (T 2 ) and longitudinal (T 1 ) relaxation times, along with proton density, to help characterize the biophysical environment of water as an independent measure of altered cellular physiology. Our results validate MRI as a sensitive tool to identify regional differences in the brains of a transgenic mouse model of Alzheimer's disease that may be associated with A␤-peptide deposition.
MATERIALS AND METHODS

Transgenic Mice
Transgenic mice expressing mutant human APP K670N,M671L protein (line Tg2576) (10) and a line of mice expressing human mutant PS1 M146V protein (line 8.9) (6) were crossed to generate offspring including parental type singly transgenic (APP and PS1) offspring, doubly transgenic PS/APP animals, and nontransgenic littermates (8) . Nine mice for each genotype (16 -23 months of age) were studied.
MRI Protocols
MRI was performed using a 7 T 40-cm bore magnet equipped with a 10-cm gradient insert capable of 1000 mT/m in 400 s (Magnex Scientific, Abingdon, UK) interfaced to an SMIS console (SMIS, Guilford, UK). Mice were initially anesthetized with isoflurane (2%) in NO 2 (75%) and O 2 (25%) and maintained with 1% of isoflurane during MR experiments using a facemask. Core body temperature was kept to 37°C using a temperature-controlled water blanket. Animals were placed in a 20 mm birdcage RF coil with a home-built mouse head holder. For T 2 measurements, a multislice spin-echo sequence was used. Imaging parameters were: one signal average, 48 slices, FOV 2.56 ϫ 2.56 cm 2 , matrix size 128 ϫ 96, echo times (TE) of 15, 20, 25, 35, 55, and 75 ms, and repetition time (TR) of 4000 ms. For T 1 measurements, an inversion prepared, segmented TurboFlash sequence based on the PURR sequence (progressively unsaturated relaxation during perturbed recovery from inversion) (11) with 64 linear time increments, 16 segments, 4 signal averages, a TR of 10 sec, a TE of 5 ms, and the same FOV and matrix as above. We also acquired high-resolution (53 ϫ 72 m in-plane and 200 m slice thickness) T 2 -weighted images of fixed PS/APP and PS mouse brains using a fast spin echo sequence. Image acquisition parameters were: FOV 13.8 ϫ 13.8 mm 2 , matrix 256 ϫ 192, TE/TR 10/6000 ms, 128 signal average, and an echo train length of 4.
Estimation of T 1 and T 2
For the calculation of T 2 , regions of interest (ROIs) were manually drawn on two consecutive slices using the STIMULATE program (12) . ROIs were placed at the level of the dorsal and ventral portions of the hippocampus, cortex (cingulate and retrosplenial), and corpus callosum (Fig. 1 ). An ROI in the muscle was used as an internal control. In order to estimate T 2 relaxation times for each ROI, a mean image intensity value was computed at different TEs and fitted to a single exponential curve with two parameters.
T 1 and proton density were calculated from ROIs drawn on a single slice covering the dorsal portion of the hippocampus, cingulate cortex, and temporal muscle. The mean signal intensities in the given ROI were fitted to a single exponential function after subtracting the image with the longest inversion time in phase sensitive fashion (13) . Proton density was calculated by normalizing image intensity of hippocampus and cingulated cortex with that of muscle.
Statistical Analysis
Means and standard deviations for T 2 , T 1 , and proton density for each ROI were calculated. Mean values were compared using Student's t-test assuming equal variance. Statistical significance was assigned for P Ͻ 0.05. Table 1 shows the T 2 values of various brain regions consisting of the hippocampus, cingulate cortex, retrosplenial cortex, corpus callosum, and muscle. When compared to age-matched nontransgenic (NTg) controls, PS/APP mice showed significantly reduced T 2 values in the cingulate (P ϭ 0.009) and retrosplenial cortex (P ϭ 0.047), and hippocampus (P ϭ 0.016). No significant differences in T 2 values were evident in the corpus callosum for NTg and PS/APP or in any brain region between PS and PS/APP or PS and NTg groups. Muscle, used as an internal control, demonstrated no differences among all three genotypes, indicating reliability of the T 2 measurements. No significant differences in T 1 relaxation times or proton density were found between the three genotypes. Shown in Fig. 2 are representative high-resolution MR images from PS and PS/APP fixed brain. Examples of A␤ immunolabeled histological images from different, but representative, PS and PS/APP mice are shown in Fig. 3 . The PS/APP histological section shows extensive amyloid deposition, while the PS histological section is void of amyloid deposition. A similar difference was observed for the presence and absence of signal hypointensities in the high-resolution MRI of PS/APP and PS mouse brains, respectively.
RESULTS
DISCUSSION
Proton density and T 1 values did not show any significant differences in the three genotypes. This is not necessarily surprising, since both T 1 and proton density are generally less sensitive to pathophysiology. The regional T 2 changes shown here in the hippocampus and cingulate and retrosplenial cortices imply alterations of cell physiology in the PS/APP mice. These regions are consistent with a previous report (14) of PS/APP mice having greater levels of amyloid deposition associated with astrocytosis in the cortex and hippocampus. Also, the highest transgene expression is present in the cortex and the CA3 region of the hippocampus (8) . Since there was no significant T 2 difference between PS/APP and PS or PS and NTg, the overexpression of APP may be the predominant factor associated with the shortening of T 2 in PS/APP mice. Although the T 2 values of PS mice are not statistically different from other genotypes, the T 2 values were shorter than those of NTg, but longer than PS/APP mice. Although this trend suggests a possible influence of PS gene expression on T 2 values, the explicit effect of gene expression on T 2 remains unknown.
It is possible that the reductions in T 2 demonstrated here might be the result of reduced cerebral blood flow (CBF). Reductions of T 2 have been associated with reduced CBF in rats (15) , which was attributed to decreased blood oxygenation in areas of diminished perfusion. In this study, T 2 reductions of 6% were associated with CBF reductions from 15-60% (15) . Recently, Niwa et al. (16) demonstrated a 40 -46% reduction of CBF and a 30 -40% reduction of cerebral glucose utilization in similar transgenic mouse models of ␤-amyloid overproduction, compared with agematched, nontransgenic littermates. Considering the high loads of ␤-amyloid in the parenchyma and cerebral vasculature of the PS/APP mice used in our study (17) , a reduction of CBF would not be surprising and indeed might contribute to the 6 -8% average reduction in T 2 observed. Interestingly, the corpus callosum, which is the only white matter region studied, did not show a significant reduction in T 2 . Since white matter baseline CBF is known to be 3-4 times less than gray matter, it might be expected that white matter T 2 would be less affected by changes in CBF.
In order to further investigate possible sources of T 2 reduction in PS/APP mice, we acquired high-resolution T 2 -weighted images of PS and PS/APP fixed mouse brain (Fig. 2) . The most striking observation is the presence of numerous signal hypointensities in the MR images of PS/ APP mice and the absence of any similar pattern of signal hypointensities in the PS mice. This is remarkably consistent with the histological pattern of distribution of plaque deposition described in the literature (7, 14) , and illus- trated here with two ␤-amyloid-immunostained histological images from different PS and PS/APP mice (Fig. 3) . Although the T 2 -weighted images presented here are not quantitative in nature, the similarity in the general pattern of distribution of histologically defined plaques and MRI signal hypointensities is intriguing and may suggest an influence of plaque on T 2 reductions as measured in the ROI analysis. Further quantitative work will be necessary in order to determine the explicit influence of plaques in T 2 .
Reduced T 2 in human AD has been associated with iron deposition in basal ganglia (18) . Although the association of iron and plaques in PS/APP mice is not known, iron has been associated with plaque in similar transgenic mouse models (19) . Therefore, the reason for the reduction in T 2 shown in the current study cannot exclude the possibility of a contribution from elevated iron levels in the plaque of PS/APP mice. Indeed, the accumulation of iron in these plaques could be responsible for the hypointensities observed in our high-resolution images.
Finally, cell shrinkage has been associated with decreased T 2 (20) and it is of interest to note that cell size is regulated by the lysosomal system (21), which is markedly activated in AD and also upregulated in PS/ APP mice (22) . Evidence of this may be elucidated by MR diffusion studies, which we are in the process of performing.
Our data demonstrate that quantitative measurements of T 2 can provide evidence of early involvement of regional pathophysiological changes in the absence of neuronal cell loss in mouse brains exhibiting amyloid plaque neuropathology. The demonstration here of disease-relevant functional abnormalities before appreciable numbers of neurons are lost underscores the promise of MRI as an aid to the early diagnosis of AD and assessment of treatment efficacy.
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